Fluoroquinolone‐Associated Psychiatric and Ocular Adverse Events: A Disproportionality Analysis Using Real‐World Data From FAERS (2011–2024)
Pharmacology Research & Perspectives · 2026
DOI: 10.1002/prp2.70206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2026. Verfasst von Hau-Tak Chau und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR. Hauptthemen laut MEDLINE: Fluoroquinolones, Mental Disorders, Anti-Bacterial Agents, Eye Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rosetrees/Stoneygate Trust, Fight for Sight/Glaucoma UK, Royal Society Research Grant.
Themen: Patientensicherheit
Abstract (Originalsprache)
Fluoroquinolones (FQs) are widely prescribed antibiotics; however, increasing concerns have arisen over their potential to cause disabling and irreversible adverse effects. Using real‐world data from the FDA Adverse Event Reporting System (FAERS) (2011–2024), we performed disproportionality analyses on psychiatric and eye‐related adverse events (AEs) using reporting odds ratios (RORs). Of 44 895 FQ‐associated adverse event reports, 8518 cases exhibited psychiatric AEs whilst 4367 cases displayed eye‐related AEs. Among six FDA‐approved FQs, three (ciprofloxacin/levofloxacin/moxifloxacin) showed safety signals for psychiatric disorders and four (ciprofloxacin/levofloxacin/moxifloxacin/ofloxacin) for eye‐related disorders. Eight psychiatric and nine eye‐related AEs were commonly reported across multiple FQs. Importantly, moxifloxacin exhibited unique safety signals for ocular‐related toxicity, including iris transillumination defect [ROR: 6604.89 (4736.76–9209.81)], iris hypopigmentation [1887.66 (1175.44–3031.42)], and pigment dispersion syndrome [2360.62 (1432.71–3889.51)], raising concern for potential progression to pigmentary glaucoma—findings not prominently featured in current safety warnings. Additionally, systematic characterization of suicide cases revealed striking male predominance despite females comprising the majority of psychiatric AEs, identifying middle‐aged males as a high‐risk demographic. These findings support the need for enhanced pharmacovigilance, particularly regarding moxifloxacin's ocular toxicity and FQs' suicide vulnerability in specific patient subgroups. When FQ prescription becomes unavoidable, robust safety monitoring should be implemented to detect early neuropsychiatric and ocular complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR.
- Department of Comparative Biomedical Sciences, School of Veterinary Medicine, University of Surrey, Guildford, UK.
ORCID-Profile: Ngan Pan Bennett Au
Förderung
- Rosetrees/Stoneygate Trust
- Fight for Sight/Glaucoma UK
- Royal Society Research Grant
- Rosetrees Trust
- Fight for Sight UK
- Royal Society
Zitieren
APA
Chau, H. T., & Au, N. P. B. (2026). Fluoroquinolone‐Associated Psychiatric and Ocular Adverse Events: A Disproportionality Analysis Using Real‐World Data From FAERS (2011–2024). Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70206
Vancouver
Chau HT, Au NPB. Fluoroquinolone‐Associated Psychiatric and Ocular Adverse Events: A Disproportionality Analysis Using Real‐World Data From FAERS (2011–2024). Pharmacology Research & Perspectives. 2026. doi:10.1002/prp2.70206
BibTeX
@article{Chau2026,
author = {Chau, Hau-Tak and Au, Ngan Pan Bennett},
title = {Fluoroquinolone‐Associated Psychiatric and Ocular Adverse Events: A Disproportionality Analysis Using Real‐World Data From FAERS (2011–2024)},
journal = {Pharmacology Research & Perspectives},
year = {2026},
doi = {10.1002/prp2.70206}
}
EUVIMED